Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (1,053 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
A malignant neoplasm consisting of elements of teratoma with those of embryonal carcinoma or choriocarcinoma, or both. It occurs most often in the testis. (Dorland, 27th ed)
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Teratocarcinomas.
Where it fits in the MeSH classification
- Broader topics
- Neoplasms, Germ Cell and Embryonal
Research landscape
PubMed indexes 737 records tagged with the MeSH heading “Teratocarcinoma” (counts retrieved 2026-10-29). 19 of them (2.6%) were published from 2020 onward, and the busiest period so far is through 1999 with 329 records.
Reviews account for 44 records (6.0%) and meta-analyses for 0. Randomized controlled trials number 0 (0.0%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 329 |
| 2000-2009 | 290 |
| 2010-2019 | 99 |
| 2020 onward | 19 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 44 | 6.0% |
| Meta-analyses | 0 | 0.0% |
| Randomized controlled trials | 0 | 0.0% |
Method: PubMed query "Teratocarcinoma"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in cancer and oncology
Cancer research spans very different kinds of evidence. Laboratory studies in cell lines and animal models reveal mechanisms but often do not translate to patients. Early-phase trials mainly test safety and dosing, while phase 3 randomized trials and their meta-analyses are the usual basis for treatment conclusions. Outcomes also differ in meaning: tumour shrinkage, progression-free survival and overall survival are not interchangeable, and screening studies can be distorted by lead-time and overdiagnosis. When reading a result, check the cancer type and stage studied, the comparison treatment, and which outcome was measured.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors | 2012 | Research article Design not recorded in structured metadata | 224 | cc by PMID 22273460 · DOI · PMC3314544 |
| Differential expression of HERV-K (HML-2) proviruses in cells and virions of the teratocarcinoma cell line Tera-1 | 2015 | Research article Design not recorded in structured metadata | 62 | cc by PMID 25746218 · DOI · PMC4379556 |
| Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines | 2010 | Research article Design not recorded in structured metadata | 60 | cc by PMID 20942921 · DOI · PMC2964638 |
| Comparative immunohistochemical characterisation of a teratoma in a domestic duck (Anas platyrhynchos) and a teratocarcinoma in a muscovy duck (Cairina moschata) | 2025 | Research article Design not recorded in structured metadata | 0 | cc by PMID 40217475 · DOI · PMC11987307 |
Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors [1]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundSeveral stromal cell subtypes including macrophages contribute to tumor progression by inducing epithelial-mesenchymal transition (EMT) at the invasive front, a mechanism also linked to metastasis.
- Closing excerpt
- As macrophage infiltration and pronounced EMT tumor phenotype correlate with increased grade in NSCLC patients, we propose that TAMs also promote tumor progression by inducing EMT locally in tumors.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (320 words)
BackgroundSeveral stromal cell subtypes including macrophages contribute to tumor progression by inducing epithelial-mesenchymal transition (EMT) at the invasive front, a mechanism also linked to metastasis. Tumor associated macrophages (TAM) reside mainly at the invasive front but they also infiltrate tumors and in this process they mainly assume a tumor promoting phenotype. In this study, we asked if TAMs also regulate EMT intratumorally. We found that TAMs through TGF-β signaling and activation of the β-catenin pathway can induce EMT in intratumoral cancer cells.MethodsWe depleted macrophages in F9-teratocarcinoma bearing mice using clodronate-liposomes and analyzed the tumors for correlations between gene and protein expression of EMT-associated and macrophage markers. The functional relationship between TAMs and EMT was characterized in vitro in the murine F9 and mammary gland NMuMG cells, using a conditioned medium culture approach. The clinical relevance of our findings was evaluated on a tissue microarray cohort representing 491 patients with non-small cell lung cancer (NSCLC).ResultsGene expression analysis of F9-teratocarcinomas revealed a positive correlation between TAM-densities and mesenchymal marker expression. Moreover, immunohistochemistry showed that TAMs cluster with EMT phenotype cells in the tumors. In vitro, long term exposure of F9-and NMuMG-cells to macrophage-conditioned medium led to decreased expression of the epithelial adhesion protein E-cadherin, activation of the EMT-mediating β-catenin pathway, increased expression of mesenchymal markers and an invasive phenotype. In a candidate based screen, macrophage-derived TGF-β was identified as the main inducer of this EMT-associated phenotype. Lastly, immunohistochemical analysis of NSCLC patient samples identified a positive correlation between intratumoral macrophage densities, EMT markers, intraepithelial TGF-β levels and tumor grade.ConclusionsData presented here identify a novel role for macrophages in EMT-promoted tumor progression. The observation that TAMs cluster with intra-epithelial fibroblastoid cells suggests that the role of macrophages in tumor-EMT extends beyond the invasive front. As macrophage infiltration and pronounced EMT tumor phenotype correlate with increased grade in NSCLC patients, we propose that TAMs also promote tumor progression by inducing EMT locally in tumors.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 22273460 · DOI · PMC3314544
Differential expression of HERV-K (HML-2) proviruses in cells and virions of the teratocarcinoma cell line Tera-1 [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Human endogenous retrovirus (HERV-K (HML-2)) proviruses are among the few endogenous retroviral elements in the human genome that retain coding sequence.
- Closing excerpt
- Consistent with the RNASeq results, we found that the activity of most LTRs corresponded to their transcript levels.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (179 words)
Human endogenous retrovirus (HERV-K (HML-2)) proviruses are among the few endogenous retroviral elements in the human genome that retain coding sequence. HML-2 expression has been widely associated with human disease states, including different types of cancers as well as with HIV-1 infection. Understanding of the potential impact of this expression requires that it be annotated at the proviral level. Here, we utilized the high throughput capabilities of next-generation sequencing to profile HML-2 expression at the level of individual proviruses and secreted virions in the teratocarcinoma cell line Tera-1. We identified well-defined expression patterns, with transcripts emanating primarily from two proviruses located on chromosome 22, only one of which was efficiently packaged. Interestingly, there was a preference for transcripts of recently integrated proviruses, over those from other highly expressed but older elements, to be packaged into virions. We also assessed the promoter competence of the 5' long terminal repeats (LTRs) of expressed proviruses via a luciferase assay following transfection of Tera-1 cells. Consistent with the RNASeq results, we found that the activity of most LTRs corresponded to their transcript levels.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 25746218 · DOI · PMC4379556
Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines [3]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundMatrix metalloproteinases (MMPs) are involved in the degradation of protein components of the extracellular matrix and thus play an important role in tumor invasion and metastasis.
- Closing excerpt
- ConclusionsIshikawa, Caski, OAW-42 and BeWo cell lines could be the best choice for all future experiments on MMP regulation and their role in endometrial, cervical, ovarian or choriocarcinoma development, whereas the teratocarcinoma cell line PA1 could be used as a positive control for general MMP experiments.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (272 words)
BackgroundMatrix metalloproteinases (MMPs) are involved in the degradation of protein components of the extracellular matrix and thus play an important role in tumor invasion and metastasis. Their expression is related to the progression of gynecological cancers (e.g. endometrial, cervical or ovarian carcinoma). In this study we investigated the expression pattern of the 23 MMPs, currently known in humans, in different gynecological cancer cell lines.MethodsIn total, cell lines from three endometrium carcinomas (Ishikawa, HEC-1-A, AN3 CA), three cervical carcinomas (HeLa, Caski, SiHa), three chorioncarcinomas (JEG, JAR, BeWo), two ovarian cancers (BG-1, OAW-42) and one teratocarcinoma (PA-1) were examined. The expression of MMPs was analyzed by RT-PCR, Western blot and gelatin zymography.ResultsWe demonstrated that the cell lines examined can constitutively express a wide variety of MMPs on mRNA and protein level. While MMP-2, -11, -14 and -24 were widely expressed, no expression was seen for MMP-12, -16, -20, -25, -26, -27 in any of the cell lines. A broad range of 16 MMPs could be found in the PA1 cells and thus this cell line could be used as a positive control for general MMP experiments. While the three cervical cancer cell lines expressed 10-14 different MMPs, the median expression in endometrial and choriocarcinoma cells was 7 different enzymes. The two investigated ovarian cancer cell lines showed a distinctive difference in the number of expressed MMPs (2 vs. 10).ConclusionsIshikawa, Caski, OAW-42 and BeWo cell lines could be the best choice for all future experiments on MMP regulation and their role in endometrial, cervical, ovarian or choriocarcinoma development, whereas the teratocarcinoma cell line PA1 could be used as a positive control for general MMP experiments.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 20942921 · DOI · PMC2964638
Comparative immunohistochemical characterisation of a teratoma in a domestic duck (Anas platyrhynchos) and a teratocarcinoma in a muscovy duck (Cairina moschata) [4]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundNeoplasms consisting of two or more germinal layers are classified as teratomas if benign or as teratocarcinomas if malignant.
- Closing excerpt
- During these examinations, a large spectrum of antibodies specific for different tissues and cells were tested on duck control tissue which can be of help for immunohistochemical examinations on avian tissues in the future.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (282 words)
BackgroundNeoplasms consisting of two or more germinal layers are classified as teratomas if benign or as teratocarcinomas if malignant. Teratomas are rare tumours occurring in a wide range of species including mammals, birds and reptiles and only a few cases have been reported in ducks with infrequent documentation of immunohistochemical characterisation. Teratocarcinomas occur rarely and, to the authors' knowledge, have not been described or immunohistochemically characterised in ducks, yet. Therefore, the clinical and pathological presentation of a teratoma in a mulard duck and a teratocarcinoma in a muscovy duck are described. In addition to a histologic examination, both tumours were characterised by applying a panel of immunohistochemical markers previously tested on duck tissue.Case presentationA mulard duck (Anas platyrhynchos x Cairina moschata) showed a mass in the cranial coelomic cavity histologically diagnosed as tridermic teratoma. A caudal coelomic mass in a Muscovy duck (Cairina moschata) was histologically diagnosed as a teratocarcinoma with metastases to the liver, mesentery and intestinal wall. An extensive immunohistochemical examination for a detailed characterisation and comparison with duck control tissue was performed in both cases, highlighting various components of the neoplastic tissues including lymphocytes, nervous and endodermal components.ConclusionsTo the authors' knowledge, this is the first report of a teratocarcinoma in a duck with intense immunohistochemical characterisation and comparison with a teratoma in another duck. Immunohistochemistry enables a more profound examination of the histogenetic composition of such neoplasms compared to histology alone. Both neoplasms should be considered as differentials for masses in body cavities of ducks. During these examinations, a large spectrum of antibodies specific for different tissues and cells were tested on duck control tissue which can be of help for immunohistochemical examinations on avian tissues in the future.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40217475 · DOI · PMC11987307
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Self-renewal of teratocarcinoma and embryonic stem cells [5]
- Research article The tumorigenicity of human embryonic stem cells [6]
- Research article Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers [7]
- Research article From teratocarcinomas to embryonic stem cells and beyond: a history of embryonic stem cell research [8]
- Research article From teratocarcinomas to embryonic stem cells [9]
- Research article The tumorigenicity of diploid and aneuploid human pluripotent stem cells [10]
References
- Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. . 2012. PMID 22273460 · DOI · PMC3314544
- Bhardwaj N, Montesion M, Roy F, Coffin JM. Differential expression of HERV-K (HML-2) proviruses in cells and virions of the teratocarcinoma cell line Tera-1. . 2015. PMID 25746218 · DOI · PMC4379556
- Schröpfer A, Kammerer U, Kapp M, Dietl J, Feix S, Anacker J. Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. . 2010. PMID 20942921 · DOI · PMC2964638
- Eikelberg DJ, Stoff M, Peters M, Legler M, Gerhauser I, Wohlsein P. Comparative immunohistochemical characterisation of a teratoma in a domestic duck (Anas platyrhynchos) and a teratocarcinoma in a muscovy duck (Cairina moschata). . 2025. PMID 40217475 · DOI · PMC11987307
- Chambers I, Smith A. Self-renewal of teratocarcinoma and embryonic stem cells. Oncogene. 2004. PMID 15378075 · DOI
- Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res. 2008. PMID 18620095 · DOI
- Sell S, Pierce GB. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest. 1994. PMID 8302019
- Solter D. From teratocarcinomas to embryonic stem cells and beyond: a history of embryonic stem cell research. Nat Rev Genet. 2006. PMID 16534514 · DOI
- Andrews PW. From teratocarcinomas to embryonic stem cells. Philos Trans R Soc Lond B Biol Sci. 2002. PMID 12028783 · DOI · PMC1692959
- Blum B, Benvenisty N. The tumorigenicity of diploid and aneuploid human pluripotent stem cells. Cell Cycle. 2009. PMID 19887907 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.